A Phase 1, Two-Stage, Dose-Escalation Study of BNC105P, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors

Phase 1

Completed

• Conditions: Solid tumours; Cancer - Other cancer types

• Registration Number: ACTRN12607000520437
• Lead Sponsor: Bionomics Limited

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-10-10
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

(i) Confirmed solid malignancy; (ii) Life-expectancy of greater than 12 weeks; (iii) No anticancer chemotherapy for the preceding 4 weeks; (iv) Adequate organ function; (v) Disease amenable to assessment by MRI; (vi) Adequate performance score (Eastern Cooperative Oncology Group score of 0-2)

Exclusion Criteria

(i) Patients must not have received other experimental agents in preceding 4 weeks; (ii) Known brain disease; (iii) Patients with various cardiovascular risk factors are excluded; (iv) Pregnancy and immune deficiency; (v) Patients on full dose anticoagulants are excluded.

Study & Design

• Study Type: Interventional
• Study Design: Not specified